New Idylla NRAS Mutation Test (CE-IVD)
- Directly on 1 FFPE tissue section
- Detecting 18 relevant mutations
18Sep
18Sep
Launch of the Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (Research Use Only)
Being the third¹ liquid biopsy test for Biocartis, the newly launched assay, Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (Research Use Only), also marks an important milestone in the partnership with the leading science and technology company Merck².
18Sep
Idylla ctBRAF Mutation Assay (Research Use Only)
A revolution in liquid biopsy cancer research.
18Sep
Study using Biocartis’ liquid biopsy BRAF assay shows new option for retreatment of melanoma patients
Biocartis is pleased to announce the publication of an important study [1] by Prof. Dr. Bart Neyns from the University Hospital in Brussels (Belgium) in the clinical oncology journal The Lancet Oncology: ‘A second chance for success with BRAF and MEK inhibitors in Melanoma’.
18Sep
Discover Idylla Explore – offering insight into your molecular data
Get connected and enjoy the advantages of Idylla Explore, a web-based application that allows you to analyze your data by providing:
18Sep
Idylla NRAS-BRAF Mutation Test receives CE-marking
Idylla™ offers complete CE-marked RAS testing for metastatic CRC.
18Sep
Biocartis launches second liquid biopsy assay
Biocartis, an innovative molecular diagnostics company, today announces the launch of its second liquid biopsy assay, the Idylla™ ctKRAS Mutation Assay (Research Use Only, RUO), which was developed in partnership with the leading science and technology company Merck1 on Biocartis’ molecular diagnostics platform Idylla™.
18Sep
Idylla platform – real-time PCR based molecular diagnostics system
Idylla™, Biocartis’ fully automated, real-time PCR based molecular diagnostics system, is designed to offer fast and easy access to clinical molecular diagnostic information, anywhere and anytime.
18Sep
Biocartis Idylla BRAF Mutation Test
Introducing Biocartis Idylla – BRAF molecular results in as little as 90 minutes.
About 50 percent of all melanomas harbor mutations in the BRAF oncogene. Idylla™ BRAF Mutation Test detects BRAF mutations directly from FFPE tissue sections in 90 minutes with less than 2 minutes hands-on time.